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Objectives: Direct application of low-energy unfocused shock waves induces angiogenesis in ischemic soft tis-
sue. The potential effects of epicardial shock wave therapy applied in direct contact to ischemic myocardium are
uncertain.
Methods: For induction of ischemic heart failure in a rodent model, a left anterior descending artery ligation was
performed in adult Sprague–Dawley rats. After 4 weeks, reoperation with (treatment group, n ¼ 60) or without
(control group, n ¼ 60) epicardial shock wave therapy was performed. Low-energy shock waves were applied in
direct contact with the infarcted myocardium (300 impulses at 0.38 mJ/m2). Additionally, healthy animals (n ¼
30) with normal myocardium were studied. Angiogenesis, ventricular function upregulation of growth factors,
and brain natriuretic peptide levels were analyzed.
Results: Histologic analysis revealed significant angiogenesis 6 weeks (treatment group: 8.2  3.7 vs control
group: 2.9  1.9 vessels per field, P ¼ .016) and 14 weeks (treatment group: 7.1  3.1 vs control group: 3.2
 1.8 vessels per field, P ¼ .011) after shock wave treatment. In the treatment group ventricular function
improved throughout the follow-up period (6 weeks: 37.4%  9% [P< .001] and 14 weeks: 39.5%  9%
[P< .001]). No improvement of ventricular function was observed in the control group (6 weeks: 28.6% 
5% and 14 weeks: 21.4%  5%). Rat brain natriuretic peptide 45 levels were lower in the treatment group
compared with those in the control group 6 and 14 weeks after treatment. Vascular endothelial growth factor,
Fms-related tyrosine kinase 1, and placental growth factor levels were upregulated after 24 and 48 hours and
7 days in the treatment group. No effects on healthy myocardium were observed.
Conclusion: Direct epicardial low-energy shock wave therapy induces angiogenesis and improves ventricular
function in a rodent model of ischemic heart failure.E
TThe increasing incidence of advanced ischemic heart failure
and the availability of traditional therapies to selected pa-
tients only has driven the need for alternative myocardial re-
generative therapies.1 Based on the consideration that
angiogenesis might reverse the pathophysiologic process
that leads to ischemic heart failure, a therapy that induces an-
giogenesis could be developed as an alternative or adjunc-
tive treatment for patients with advanced ischemic heart
failure.
Defocused low-energy shock wave therapy (SWT) ap-
plied in direct contact to ischemic tissue induces angiogene-
sis and, consecutively, tissue regeneration in ischemic limbs,
skin flaps, and vascular ulcers.2-6 However, the effects of
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cardium are uncertain.
To address this issue, we tested a system for direct epicar-
dial SWT and initiated an experimental study in a rodent
model of ischemia-induced heart failure. We measured the
effect of direct epicardial SWT on angiogenesis and fol-
lowed the animals by means of echocardiographic analysis
to study the efficacy of this treatment in the reversal of
impaired left ventricular (LV) function. Upregulation of
growth factors and development of brain natriuretic peptide
(BNP) levels were analyzed. Furthermore, we studied the
effects of direct epicardial SWT on healthy myocardium.
MATERIALS AND METHODS
The Institutional Animal Care and Use Committee at the Medical Uni-
versity of Vienna approved this study (GZ: 66.009/0176-BrGT/2005, GZ:
66.009/0217-BrGT/2006). Operations and animal care were provided in
accordance with the ‘‘Guide for the care and use of laboratory animals’’
(National Institutes of Health, volume 25, no. 28, revised 1996).
Experimental Animals
A total of 210, random, 8- to 10-week-old Sprague–Dawley rats (240–
280 g) were obtained from the ‘‘Institut fu¨r Labortierkunde und Genetik’’
(Himberg, Austria) and inbred in a pathogen-free facility under strict veter-
inary supervision and maintained in controlled conditions with 12-hour
light/dark cycles. The animals received a commercial rat diet and water
ad libitum.Cardiovascular Surgery c Volume 137, Number 4 963
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TAbbreviations and Acronyms
BNP ¼ brain natriuretic peptide
Flt-1 ¼ Fms-related tyrosine kinase 1
LAD ¼ left anterior descending artery
LV ¼ left ventricular
PCR ¼ polymerase chain reaction
PlGF ¼ placental growth factor
SWT ¼ shock wave therapy
VEGF ¼ vascular endothelial growth factor
vWF ¼ von Willebrand factor
Induction of myocardial infarction was performed in 180 rats according
to a standardized model by means of left anterior descending artery (LAD)
ligation.7 Animals were anesthetized with ketamine (100 mg/kg), xylazine
(Rompum; 10 mg/kg), and isoflurane (2%) and ventilated after orotracheal
intubation. LAD ligation was performed through a left minithoracotomy,
the pericardium was opened, and the proximal LAD was ligated with Pro-
lene 6-0 sutures to induce a sizable LV infarct. A total of 122 rats survived
the LAD ligation. Thirty rats underwent thoracotomy without LAD ligation
under the same conditions.
Four weeks after LAD ligation, the surviving 120 animals with large,
echocardiographically proved LV infarcts were randomized to one of 2
groups: reoperation with (treatment group, n ¼ 60) and reoperation without
(control group, n ¼ 60) SWT. For reoperation, animals were anesthetized
with ketamine (100 mg/kg), xylazine (10 mg/kg), and isoflurane (2%)
and ventilated after orotracheal intubation. Rethoracotomy was performed,
and the heart was dissected free from the thoracic wall. Homemade air-filled
plastic bags were positioned around the heart to expose the LV anterior wall
and to avoid shock wave–induced lung injury.8 A commercially available
ultrasound gel serving as contact medium was applied to the LV anterior
wall of the heart (Aquasonic; Parker Laboratories, Inc, Fairfield, NJ; Fig-
ure 1, A). In the treatment group a total of 300 shock wave impulses were
applied to the LV anterior wall by using a CardioGold (CRT/MTS-Europe
GmbH, Konstanz, Germany) SWT system and a specially designed applica-
tor (CRT/MTS-Europe GmbH; Figure 1, B). An identical procedure without
application of SWT was performed in the control group.
To investigate the effects of SWT on healthy myocardium, a third group
was studied (SWT only, n ¼ 30): thoracotomy without LAD ligation and, 4
weeks later, rethoracotomy with SWT on healthy noninfarcted myocar-
dium.
Animals were killed 6 and 14 weeks after treatment, hearts were har-
vested and processed for immunohistochemistry, and serum was processed
for enzyme-linked immunosorbent assays. For real-time polymerase chain
reaction (PCR) and Western blotting of proangiogenic cytokines, a subpop-
ulation of animals was killed 24 and 48 hours and 7 days after reoperation.
Shock Wave Therapy
The CardioGold (CRT/MTS-Europe GmbH) SWT system and the used
handheld applicator (CRT/MTS-Europe GmbH) were developed for the di-
rect epicardial application of SWT (Figure 1, A). In contrast to SWT systems
for nephrolithiasis or percutaneous cardiac SWT that produced focused
shock waves, the CardioGold uses a parabolic reflector that produces unfo-
cused, nearly parallel shock waves that allow treatment of a target area with
a diameter of 0.5 to 0.7 mm and a penetration depth of 1 to 1.5 cm. The used
energy flux density (0.38 mJ/mm2) and the cumulative treatment dose are
based on our experience with the treatment of acute and chronic wounds,
as well as diabetic and vascular ulcers, compared with that used for percu-
taneous cardiac SWT and represent about 10% of that used for lithotripsy.6964 The Journal of Thoracic and Cardiovascular SuImmunohistochemistry and Quantitative Histology
Tissue was processed for paraffin embedding, and serial sections were
stained with hematoxylin and eosin, Goldner, and a polyclonal anti-von
Willebrand factor (vWF) antibody (Abcam, Cambridge, United Kingdom).
Briefly, deparaffinized sections were preincubated with 3%H2O2 and horse
serum (Jackson ImmunoResearch, West Grove, Pa) to block endogenous
peroxidase and antigen activity before incubation with the primary antibody
(vWF, 1:200 dilution). Biotinylated anti-mouse/rabbit IgG (HþL) secondary
antibody (Vector Laboratories, Inc, Burlingame, Calif) was used to detect
positive staining, followed by streptavidin–biotin peroxidase complex
(LSAB2 streptavidin–horseradish peroxidase; DakoCytomation,
Glostrup, Denmark). For quantitative histology, digitalized images were
made with a Nikon inverted microscope Eclipse TE2000-U (Nikon Instru-
ments Europe B.V., Badhoevedorp, The Netherlands) at 403 magnifica-
tion. Quantification was performed with Lucia G image analysis software.
Six fields of the myocardial wall in the region of the LAD were evaluated
in each heart. Angiogenesis and microvascular density were evaluated ac-
cording to established procedures.9 The number of vessels was counted,
and vessel lumen areas, vessel wall thickness, and vessel width were mea-
sured. Vessels were divided into 3 sizes (small, 0–9 mm; medium, 10–19
mm; large,>20 mm). Additionally, the number of vWFþcells was obtained.
A single observer in an observer-blinded fashion performed all analyses.
Echocardiographic Analysis
Before LAD ligation, before SWT or sham operation, and before
termination (6 and 14 weeks after SWT), echocardiographic analysis was
performed (Philips iE33; Philips Medical Systems, Bothell, Wash;
Transducer: S12-1). Rats were anesthetized with isoflurane. Standardized
views of the heart were obtained at the papillary muscle level. Ejection frac-
tion and LV diameters and volumes were obtained. Examinations were dig-
italized and evaluated by an independent experienced investigator.
Real-Time PCR Analysis
Total RNA was isolated from rat heart tissue (anterior wall) by using
a TRIzol extraction (Invitrogen, Lofer, Austria), according to the manufac-
turer’s protocol. cDNA was synthesized with M-MuLV Reverse Transcrip-
tase (Fermentas, Burlington, Ontario, Canada) and 2mg of total RNA primed
with oligo dT-primer. After reverse transcription of RNA into cDNA, real-
time PCR was used to monitor gene expression with the FastStart DNA Mas-
ter SYBR Green kit and a LightCycler instrument (Roche Applied Science,
Vienna, Austria), according to the standard procedure. The primer sequences
(sense/antisense) were vascular endothelial growth factor (VEGF): 50-
TCCTGCAGCATAGCAGATGT-30/50-GCGAGTCTGTGTTTTTGCAG-
30; placental growth factor (PlGF): 50-ACTGTGTGGCGCTAAAGACA-30/
50-TTCCTCAGTCTGTGGGGTTT-30; and Fms-related tyrosine kinase 1
(Flt-1): 50-GGAGGCGAGGATTACAGTGA-30/50-GGAGGCGAGGAT
TACAGTGA-30. LCDA Version 3.5.28 was used for PCR data analysis
(Roche Applied Science). The specificity of the amplification product was
determined by performing a melting curve analysis. Standard curves for ex-
pression of each gene were generated by means of serial dilution of known
quantities of the respective cDNA gene template. Relative quantification
of the signals was done by normalizing the signals of the different genes
with the b2-microglobulin signal. Measurements were done in triplicate.
Western Blotting
Rat heart tissues were lysed in solubilization buffer (10 mmol/L Tris–
HCl, 50 mmol/L NaCl, 1% Triton X-100, 30 mmol/L sodium pyrophos-
phate, 100 mmol/L Na3VO4, 1 mmol/L phenylmethylsulfonyl fluoride,
and 13 Complete ethylenediamine tetraacetic acid–free Protease Inhibitor
Cocktail (Roche Applied Science). Insoluble material was removed by
means of centrifugation (15,000 rpm for 15 minutes at 4C). Tissue lysates
(50 mg per lane) were separated by means of sodium dodecylsulfate–poly-
acrylamide gel electrophoresis before electrophoretic transfer onto 0.2-mmrgery c April 2009
Zimpfer et al Evolving TechnologyFIGURE 1. A, Direct epicardial shock wave therapy. B, Technical drawing of the applicator for direct epicardial shock wave therapy.E
Tsupported nitrocellulose membrane (Bio-Rad Laboratories, Hercules, Ca-
lif). The blots were probed with polyclonal antibodies against VEGF and
PlGF (Santa Cruz Biotechnology, Inc, Santa Cruz, Calif) before incubation
with horseradish peroxidase–conjugated secondary antibodies (GE Health-
care, Buckinghamshire, United Kingdom; Millipore, Billerica, Mass). Pro-
teins were detected on the membrane by using SuperSignal West Pico
Chemolumninescent Substrate (Pierce, Rockford, Ill), and specific protein
bands were quantified by normalizing the signals of the different proteins
to the Ponceau S stain of the membrane with ImageQuant Version 5.0 soft-
ware (Molecular Dynamics, Sunnyvale, Calif).
Enzyme-Linked Immunosorbent Assay for Rat
BNP-45
Enzyme-linked immunosorbent assay for rat BNP-45 (AssayMax; As-
sayPro, St Charles, Mo) was performed according to the manufacturer’s
protocol. Fifty microliters of standard or a serum sample were added to
each well. The wells were incubated for 2 hours at room temperature and
then aspirated and washed 5 times. Biotinylated rat BNP-45 antibody
(200 mL) was added to each well and incubated for 2 hours at room temper-
ature, followed by 5 washes. Then 50 mL of streptavidin–peroxidase conju-
gate was added and incubated for 30 minutes at room temperature, followed
by 5 washes. Afterward, 50 mL of chromogen substrate solution was added
to each well and incubated for 7 minutes at room temperature. The reaction
was stopped by adding 50 mL of stop solution. Then the optical density was
detected immediately by using a microplate reader (Anthos, Salzburg,
Austria) at 450 nm.
Statistical Analysis
Statistical analysis was performed with SPSS 14.0 software (SPSS, Inc,
Chicago, Ill). Categorical variables are expressed as frequency distributions
and percentages; continuous variables are expressed as means  standard
deviation. Categorical variables were compared by means of c2 or Fisher’s
exact tests, as appropriate. Continuous variables were either compared with
analysis of variance (Bonferroni) after testing for normality of distribution
or the Mann–Whitney test.
RESULTS
Animal Outcome
A total of 122 rats were alive 4 weeks after LAD ligation.
Of those, 2 had only minor LV infarcts and were excludedThe Journal of Thoracic and Cfrom further analysis. The remaining 120 rats with large,
echocardiographically proved LV infarcts were randomized
to the treatment and control groups in a 1:1 ratio. On reoper-
ation, 4 animals in the treatment group and 5 animals in the
control group died immediately after induction of anesthe-
sia. No deaths were observed during or after SWT. No
deaths occurred in the SWT-only group.
Quantitative Histology and Immunohistochemistry
Quantitative histology of the LV anterior wall revealed
more and larger vessels, indicating a higher microvascular
density in the treatment group compared with the control
group 6 and 14 weeks after treatment (Figure 2). We ob-
served more vWFþ endothelial cells in the treatment group
compared with the control group 6 and 14 weeks after treat-
ment (Figure 3, A). Fourteen weeks after treatment, we
found more vital cells in the area of myocardial infarction
in the treatment group compared with the control group (Fig-
ure 3, B). Quantitative histology of the (noninfarcted) LV
posterior wall revealed no difference in microvascular den-
sity and endothelial cells, as well as vital cell count, 6 and
14 weeks after treatment. In SWT-only animals we observed
no structural changes of the myocardium in the treated area.
Furthermore, we could not detect any histologic signs of
myocardial damage, including cellular infiltrates, extrava-
sates, edema, cell membrane, or cell nuclei damage and
hypertrophy.
Ventricular Function
Baseline LV ejection function was comparable between
the treatment and control groups (treatment group, 59.0%
 4%; control group, 55.7% 9%; P¼ .581). Four weeks
after LAD ligation (before reoperation with or without treat-
ment), LV function was impaired in the treatment (21.3%
10%) and control (21.6%  7%) groups compared withardiovascular Surgery c Volume 137, Number 4 965
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TFIGURE 2. A, Microvascular density and vessel size expressed as the number of vessels per field ( standard deviation) in the treatment and control groups
6 weeks after treatment. *P< .05, treatment versus control groups. B, Microvascular density and vessel size expressed as the number of vessels per field
( standard deviation) in the treatment and control groups 14 weeks after treatment. *P< .05, treatment versus control groups. C, Factor VIII staining of
the anterior wall treatment group. D, Factor VIII staining of the anterior wall control group.baseline values (both P< .0001). In the treatment group LV
function improved 6 (37.4% 9%,P<.001) and 14 (39.5%
 9%, P< .001) weeks after SWT. LV function remained
impaired in the control group 6 (28.6%  5%) and 14
(21.4%  5%) weeks after treatment (Figure 4). In SWT-
only animals with noninfarcted myocardium, we observed
normal LV function throughout the entire study period.
Expression of VEGF, Flt-1, and PlGF
We observed an upregulation of mRNA levels of VEGF,
Flt-1, and PlGF 24 and 48 hours and 7 days after treatment
in the treatment group compared with the control group (Fig-
ure 5, A-C). Furthermore, we observed an upregulation of
VEGF protein level 7 days after treatment in the treatment
group compared with the control group (Figure 5,D). We ob-
served no significant commensurate upregulation of PlGF
24 and 48 hours and 7 days after treatment. Six and 14 weeks
after treatment, we observed no difference in mRNA and
protein levels of VEGF, Flt-1, and PlGF in the treatment
group compared with the control group (data not shown).966 The Journal of Thoracic and Cardiovascular SuSerum Levels of Rat BNP-45
We measured lower serum levels of rat BNP-45 6 and 14
weeks after treatment in the treatment group compared with
the control group (Figure 6). The lowest (normal) serum
levels of rat BNP-45 were observed in SWT-only animals
throughout the study period.
DISCUSSION
We demonstrate that direct epicardial SWT induces an-
giogenesis and reverses ischemic heart failure, as shown
by improved LV function and lower serum levels of BNP
in a rodent model of ischemic heart failure.
Based on the broad clinical experience with percutane-
ous lithotripsy, first studies on SWT for myocardial regen-
eration followed the principle of distant percutaneous
application.10-14 These studies generated knowledge on
the regenerative potential of SWT of ischemic myocar-
dium, as demonstrated by induction of angiogenesis, re-
duction of infarct size, and improvement of ventricular
function in pig models.11,13 First experience in a veryrgery c April 2009
Zimpfer et al Evolving TechnologyFIGURE 3. A, Number of endothelial (Factor VIII–positive) cells per field ( standard deviation) 6 and 14 weeks after treatment in the treatment and control
groups.Black bar Treatment group; white bar, control group. *P< .05, treatment versus control groups. B, Number of vital cells per field ( standard de-
viation) in the infarct scar 6 and 14 weeks after treatment in the treatment and control groups. Black bar, myocardial infarction with shock wave therapy;
white bar, myocardial infarction without shock wave therapy. *P< .05, treatment versus control groups.E
Tlimited clinical series of patients with diffuse coronary
artery disease not amendable to percutaneous or surgical
revascularization indicates that percutaneous cardiac
SWT induces relief of symptoms of angina pectoris.12,14
Results with regard to improvement of exercise capacity
and regional myocardial perfusion remain inconsistent.12,14
Despite these preliminary encouraging results, percutane-
ous SWT has not achieved broad clinical acceptance to
date, most probably because of the fact that only micro-
spots of ischemic myocardium can be treated with percuta-
neous SWT and treatment of whole infarct scars or large
ischemia in single sessions is impossible.12,14 This fact ne-
cessitates repeated treatment sessions to treat a substantial
amount of the whole ischemic area, which renders this
technique time-consuming, expensive, and complex.11-14
A more defocused application allowing treatment of larger
ischemic areas is limited by the dependence on appropriate
acoustic windows because shock waves can severely
injure lung tissue if applied over it.15 Considering the im-
pressive angiogenic potential of defocused low-energy
shock waves applied in direct contact with ischemic soft
tissues, we therefore tested a therapy system for low-
energy unfocused direct epicardial SWT.2-6 The obvious
benefit of direct epicardial SWT is that the open approach
allows precise identification of treatment areas and enables
treatment of whole infarct scars and large areas of diffusely
diseased myocardium in a single session with a justifiable
expenditure of time in combination with conventional
bypass surgery.The Journal of Thoracic andDirect epicardial SWT effectively induced significant an-
giogenesis throughout the entire follow-up period, as dem-
onstrated by means of histologic analysis. We detected
increased numbers of small, medium, and large vessels, as
well as vWFþ endothelial cells, in treated areas of ischemic
myocardium. This intense angiogenic effect relates to the
observed early upregulation of VEGF, Flt-1, and PlGF.
VEGF and Flt-1 are well-defined promoters of angiogene-
sis16-18 and have been shown to induce angiogenesis and im-
prove regional blood flow in preclinical and first clinical
studies when injected into areas of chronic limb ischemia




























FIGURE 4. Development of left ventricular function expressed as left ven-
tricular ejection fraction (LVEF; percentage  standard deviation) in the
treatment and control groups. Solid line, Treatment group; dotted line, con-
trol group. *P< .05 compared with before left anterior descending artery
(LAD) ligation. yP< .05, treatment versus control groups.Cardiovascular Surgery c Volume 137, Number 4 967
Evolving Technology Zimpfer et al
E
TFIGURE 5. A, Expression of vascular endothelial growth factor (VEGF) mRNA in the treatment and control groups 24 and 48 hours and 7 days after treat-
ment. Black bar, Treatment group;white bar, control group. *P<.05, treatment versus control groups. B, Expression of Fms-related tyrosine kinase 1 (FLT1)
mRNA in the treatment and control groups 24 and 48 hours and 7 days after treatment. Black bar, Treatment group; white bar, control group. *P<.05, treat-
ment versus control groups. C, Expression of placental growth factor (PlGF) mRNA in the treatment and control groups 24 and 48 hours and 7 days after
treatment. Black bar, Treatment group; white bar, control group. *P< .05, treatment versus control groups. D, Expression of vascular endothelial growth
factor (VEGF) protein in the treatment and control groups 24 and 48 hours and 7 days after treatment. Black bar, Treatment group; white bar, control group.
*P< .05, treatment versus control groups.and Flt-1 has previously been shown to induce angiogenesis
in ischemic soft tissues, including myocardium, after
SWT.2,4,11 However, VEGF and Flt-1 alone induce only
transient angiogenesis, and the majority of vessels regresses
when the angiogenic stimulus fades away.16,17,22 The sus-
tainability of the angiogenic effect throughout the entire
follow-up period might be explained by the concomitant
up-regulation of PlGF. PlGF reportedly amplifies the angio-
genic activity of VEGF, induces further VEGF release from
fibroblasts, and, most importantly, stimulates the maturation
of vessels through coverage with smooth muscle cells,
which leads to stabilization and durability of new ves-
sels.23-25 Therefore the observed upregulation of VEGF in
combination with PlGF might be responsible for the stable
angiogenetic effect observed after a single application of
SWT. Although the exact mechanism of mechanotransduc-
tion that links the extracellular stimulus of SWT to the968 The Journal of Thoracic and Cardiovascular Suupregulation of proangiogenetic cytokines remains uncer-
tain, there is growing evidence that cavitation phenomena
that occur during SWT induce localized stress on cell mem-
branes, with consecutive membrane hyperpolarization and
ras activation.26-28 Moreover, SWT has been shown to in-
duce nonenzymatic nitric oxide synthesis and induction of
stress fibers and intracellular gaps.27,28 Nevertheless, the
precise mechanisms for the shock wave–induced biochemi-
cal effects remains to be examined.
A single application of direct epicardial SWT resulted in
a durable improvement of LV function, as assessed by
means of echocardiographic analysis. With regard to im-
provement of LV function, various synergistic mechanisms
have to be discussed. SWT-induced angiogenesis appears to
play a primary role for the improved myocardial function.
Angiogenesis in chronic ischemic myocardium and border
zones of myocardial infarcts has been shown to reverse thergery c April 2009
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Tprocess of inadequate oxygenation and nutrient supply to
ischemic but viable myocardium, thereby promoting the
survival of tenuous cardiomyocytes and preventing the
process of apoptosis and collagen deposition that leads to
ventricular dilatation and ventricular remodeling.29,30 Fur-
thermore, the observed shock wave–mediated improvement
of cell survival in the infarct and the infarct border zone
might attenuate the process of scar thinning, which promotes
the deleterious process of progressive ventricular dilation
and remodeling.31,32 This buttressing effect to the infarcted
ventricular wall with improvement of the infarct’s passive
mechanical properties might be similar to that reported after
cellular transfer.31,32 The efficacy of SWT on reversal of im-
paired ventricular function in the animal model is supported
by our measures of the serum levels of BNP as a marker for
the prognosis of ischemic heart failure.33 Lower serum
levels of BNP throughout the entire follow-up period of 14
weeks indicate a significant and beneficial effect of SWT
on heart failure.
The extent of angiogenesis and improvement of ventricu-
lar function after direct epicardial SWT in the present study
compares with published results on gene therapy and cell
transplantation with regard to induction of angiogenesis
and improvement of ventricular function.32,34 Although
the initiating stimulus is different, cell therapy and SWT
seem to have a common final path. The main benefit of direct
epicardial SWT is its reproducibility and ease, which renders
this technology convenient for surgical use as an adjunctive
to bypass surgery.
FIGURE 6. Rat brain natriuretic peptide 45 serum levels expressed as pi-
cograms per milliliter ( standard deviation) 6 and 14 weeks after treatment
in the treatment and control groups. Black bar, Treatment group; white bar,
control group. *P< .05, treatment versus control groups.The Journal of Thoracic and CIn summary, direct epicardial SWT induces angiogenesis
and reverses symptoms of ischemic heart failure, as shown
by improved LV function and lower serum levels of BNP.
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